多沙米诺 | 55286-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噁庚英
• 中文名称: 多沙米诺
• 中文别名: 多沙胺醇
• 英文名称: Doxaminol
• 英文别名: 1-[2-(6,11-dihydrobenzo[c][1]benzoxepin-11-yl)ethyl-methylamino]-3-phenoxypropan-2-ol
• CAS: 55286-56-1
• 化学式: C₂₆H₂₉NO₃
• 分子量: 403.5
• InChiKey: SZQLTQPHXXXMNC-UHFFFAOYSA-N

物化性质

• 沸点：
  569.7±50.0 °C(Predicted)
• 密度：
  1.146±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Somatostatin antagonists and agonists
  申请人：——

  公开号：US20020091090A1

  公开（公告）日：2002-07-11

  Compounds according to the formula A-B-Z-W, wherein A is selected from (C 6 -C 10 )aryl-, or (C 1 -C 9 )heteroaryl-, which groups may be optionally substituted; B is selected from (a) O, NH, NR 10 , —(CH 2 ) k —O—, —(CH 2 ) k —N—, and —(CH 2 ) k —NR 10 —, where R 10 is (C 1 -C 6 )alkyl and where k is 1 to 6 in each case, or 1 where said group (i) through (iv) is optionally substituted by 1 to 4, preferably 1 to 2, groups selected from (C 1 -C 6 )alkyl, halo, and (C 1 -C 6 )alkyl optionally substituted by 1 to 3 halo atoms wherein one of carbon atoms C 1 , C 2 , C 3 and C 4 of said piperidine or piperazine group is optionally replaced by a carbonyl group; Z and W are as herein described; and pharmaceutically acceptable salts, solvates or hydrates thereof; pharmaceutical compositions thereof; and methods useful to facilitate secretion of growth hormone(GH) in mammels.

  根据公式A-B-Z-W，其中 A选自(C6-C10)芳基或(C1-C9)杂环芳基，这些基团可以选择性地被取代； B选自 (a) O、NH、NR10、—(CH2)k—O—、—(CH2)k—N—和—(CH2)k—NR10—，其中R10为(C1-C6)烷基，k在每种情况下为1至6，或 1所述的该组(i)至(iv)可以选择性地被1至4个，优选1至2个，选自(C1-C6)烷基、卤素和(C1-C6)烷基，该烷基可以选择性地被1至3个卤原子取代，其中所述哌啶或哌嗪基团的碳原子C1、C2、C3和C4中的一个可以选择性地被羰基取代； Z和W如本文所述；以及其药学上可接受的盐、溶剂化合物或水合物；其制药组合物；以及用于促进哺乳动物分泌生长激素(GH)的方法。
• NOVEL BRONCHODILATING DIAZAHETEROARYLS
  申请人：Johansson Martin

  公开号：US20120040942A1

  公开（公告）日：2012-02-16

  The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.

  这项发明涉及具有通式（I）的新化合物，这些化合物可用于治疗由支气管痉挛引起的疾病或疾病，例如慢性阻塞性肺疾病（COPD）和哮喘。
• [EN] NOVEL BRONCHODILATING DIAZAHETEROARYLS<br/>[FR] NOUVEAUX DIAZAHÉTÉROARYLES BRONCHODILATATEURS
  申请人：RESPIRATORIUS AB

  公开号：WO2010097410A1

  公开（公告）日：2010-09-02

  The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.

  这项发明涉及具有通式（I）的新化合物，这些化合物可用于治疗由支气管痉挛引起的疾病或疾病，例如慢性阻塞性肺疾病（COPD）和哮喘。
• Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
  申请人：——

  公开号：US20020091125A1

  公开（公告）日：2002-07-11

  Compounds according to the formula A-Z-W as herein described, wherein A is selected from the groups consisting of: A′—(CH 2 ) n —, A′—(CH 2 ) n SO 2 —, and A′—(CH 2 ) n CO—, where n is 0 to 4; and A′ is selected from (a) (C 6 -C 10 )aryl-, or (b) (C 1 -C 9 )heteroaryl-; which groups may be optionally substituted; and pharmaceutically acceptable salts, solvates or hydrates thereof; pharmaceutical compositions thereof; and methods useful to facilitate secretion of growth hormone(GH) in mammals.

  根据本文描述的公式A-Z-W，其中A是从以下组中选择的：A′—(CH2)n—，A′—(CH2)nSO2—和A′—(CH2)nCO—，其中n为0到4；A′是从(a) (C6-C10)芳基-，或(b) (C1-C9)杂环芳基-中选择的；这些基团可以选择性地被取代；以及其药学上可接受的盐、溶剂化合物或水合物；以及其中的药物组合物；以及用于促进哺乳动物中生长激素（GH）分泌的方法。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。